<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">12735</article-id><article-id pub-id-type="doi">10.7554/eLife.12735</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Advance</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Elevation of CpG frequencies in influenza A genome attenuates pathogenicity but enhances host response to infection</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-45441"><name><surname>Gaunt</surname><given-names>Eleanor</given-names></name><aff><institution content-type="dept">Infection and Immunity Division, Roslin Institute</institution>, <institution>University of Edinburgh</institution>, <addr-line><named-content content-type="city">Edinburgh</named-content></addr-line>, <country>United Kingdom</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-45442"><name><surname>Wise</surname><given-names>Helen M</given-names></name><aff><institution content-type="dept">Department of Engineering and Physical Sciences</institution>, <institution>Heriot Watt University</institution>, <addr-line><named-content content-type="city">Edinburgh</named-content></addr-line>, <country>United Kingdom</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-45443"><name><surname>Zhang</surname><given-names>Huayu</given-names></name><aff><institution content-type="dept">Infection and Immunity Division, Roslin Institute</institution>, <institution>University of Edinburgh</institution>, <addr-line><named-content content-type="city">Edinburgh</named-content></addr-line>, <country>United Kingdom</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-45444"><name><surname>Lee</surname><given-names>Lian N</given-names></name><aff><institution content-type="dept">Nuffield Department of Medicine</institution>, <institution>University of Oxford</institution>, <addr-line><named-content content-type="city">Oxford</named-content></addr-line>, <country>United Kingdom</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-18325"><name><surname>Atkinson</surname><given-names>Nicky J</given-names></name><aff><institution content-type="dept">Infection and Immunity Division, Roslin Institute</institution>, <institution>University of Edinburgh</institution>, <addr-line><named-content content-type="city">Edinburgh</named-content></addr-line>, <country>United Kingdom</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-45445"><name><surname>Nicol</surname><given-names>Marlynne Quigg</given-names></name><aff><institution content-type="dept">Infection and Immunity Division, Roslin Institute</institution>, <institution>University of Edinburgh</institution>, <addr-line><named-content content-type="city">Edinburgh</named-content></addr-line>, <country>United Kingdom</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-45446"><name><surname>Highton</surname><given-names>Andrew J</given-names></name><aff><institution content-type="dept">Nuffield Department of Medicine</institution>, <institution>University of Oxford</institution>, <addr-line><named-content content-type="city">Oxford</named-content></addr-line>, <country>United Kingdom</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15615"><name><surname>Klenerman</surname><given-names>Paul</given-names></name><aff><institution content-type="dept">Nuffield Department of Medicine</institution>, <institution>University of Oxford</institution>, <addr-line><named-content content-type="city">Oxford</named-content></addr-line>, <country>United Kingdom</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-45447"><name><surname>Beard</surname><given-names>Philippa M</given-names></name><aff><institution content-type="dept">Infection and Immunity Division, Roslin Institute</institution>, <institution>University of Edinburgh</institution>, <addr-line><named-content content-type="city">Edinburgh</named-content></addr-line>, <country>United Kingdom</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-45448"><name><surname>Dutia</surname><given-names>Bernadette M</given-names></name><aff><institution content-type="dept">Infection and Immunity Division, Roslin Institute</institution>, <institution>University of Edinburgh</institution>, <addr-line><named-content content-type="city">Edinburgh</named-content></addr-line>, <country>United Kingdom</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-35893"><name><surname>Digard</surname><given-names>Paul</given-names></name><aff><institution content-type="dept">Infection and Immunity Division, Roslin Institute</institution>, <institution>University of Edinburgh</institution>, <addr-line><named-content content-type="city">Edinburgh</named-content></addr-line>, <country>United Kingdom</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-18030"><name><surname>Simmonds</surname><given-names>Peter</given-names></name><aff><institution content-type="dept">Infection and Immunity Division, Roslin Institute</institution>, <institution>University of Edinburgh</institution>, <addr-line><named-content content-type="city">Edinburgh</named-content></addr-line>, <country>United Kingdom</country><email>Peter.Simmonds@ed.ac.uk</email></aff><xref ref-type="fn" rid="conf1"/></contrib></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-16032"><name><surname>Lipsitch</surname><given-names>Marc</given-names></name><role>Reviewing editor</role><aff><institution>Harvard School of Public Health</institution>, <country>United States</country></aff></contrib></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>16</day><month>02</month><year>2016</year></pub-date><elocation-id>e12735</elocation-id><history><date date-type="received"><day>05</day><month>11</month><year>2015</year></date><date date-type="accepted"><day>15</day><month>02</month><year>2016</year></date></history><permissions><copyright-statement>Â© 2016, Gaunt et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Gaunt et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><abstract><p>Previously, we demonstrated that frequencies of CpG and UpA dinucleotides profoundly influence the replication ability of echovirus 7 (Tulloch et al., 2014). Here, we show that that influenza A virus (IAV) with maximised frequencies of these dinucleotides in segment 5 showed comparable attenuation in cell culture compared to unmodified virus and a permuted control (CDLR). Attenuation was also manifested in vivo, with 10-100 fold reduced viral loads in lungs of mice infected with 200PFU of CpG-high and UpA-high mutants. However, both induced powerful inflammatory cytokine and adaptive (T cell and neutralising antibody) responses disproportionate to their replication. CpG-high infected mice also showed markedly reduced clinical severity, minimal weight loss and reduced immmunopathology in lung, yet sterilising immunity to lethal dose WT challenge was achieved after low dose (20PFU) pre-immunisation with this mutant. Increasing CpG dinucleotide frequencies represents a generic and potentially highly effective method for generating safe, highly immunoreactive vaccines.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Viruses</kwd></kwd-group></article-meta></front><back><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All animal experiments were carried out under the authority of a UK Home Office Project Licence (60/4479) within the terms and conditions of the strict regulations of the UK Home Office 'Animals (scientific procedures) Act 1986' and the Code of Practice for the housing and care of animals bred, supplied or used for scientific purposes.</p></fn></fn-group></back></article>